SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane | Journal of Experimental & Clinical Cancer Research | Full Text

SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane | Journal of Experimental & Clinical Cancer Research | Full Text

SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The sc...

Authors:Hui Li, Mingming Zhang, Yanli Wei, Farhan Haider, Yitong Lin, Wen Guan, Yanbin Liu, Shaoyang Zhang, Ronghua Yuan, Xia Yang, Shulan Yang and Haihe Wang

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:81

Content type:Research

Published on: 7 May 2020

• ViewFull Text
 
• ViewPDF